Background and aims: In Crohn's disease, correlation between clinical assessment and disease activity at tissue level is weak. Our aim was to evaluate the value of serum calprotectin as a biomarker for Crohn's disease. Methods: The STORI trial patients (n = 115) were studied at baseline, in clinical remission before infliximab withdrawal, or at the time of relapse after infliximab withdrawal. Forty healthy controls were also studied. Serum calprotectin level was measured by ELISA. Data were analyzed through correlation analyses, Kaplan Meier curves and Cox model, using available Crohn's Disease Activity Index (CDAI), Crohn's Disease Endoscopic Index of Severity (CDEIS), fecal calprotectin and C-reactive protein levels (hsCRP). Results: Median serum calprotectin was 8892 ng/mL (range: 410-125,000 ng/mL) in Crohn disease patients as compared with 1318 ng/mL (range: 215.8-3770 ng/mL) in controls (P b 0.0001). Serum calprotectin was significantly higher for active disease (median = 19,584 ng/mL) than for inactive A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
In Crohn's disease (CD), the correlation between simple clinical assessment and disease activity at the tissue level is weak. Hence the prediction of tissue healing, disease relapse and disease progression remains a challenge. Despite active research in the field, few biomarkers have proved to be useful for the assessment and monitoring of CD. Fecal calprotectin is one of the most informative. Calprotectin is an heterodimer made of Myeloid Related Protein 8 and 14 (MRP8 and MRP14) and represents about 40% to 60% of the proteins in the neutrophil cytosol. 1, 2 Fecal concentration of calprotectin is increased in the presence of intestinal inflammation and its measurement has been used to differentiate between irritable bowel syndrome and inflammatory bowel disease (IBD). 3 Fecal calprotectin also correlates with the endoscopic activity of CD as measured by the Crohn's Disease Endoscopic Index of Severity (CDEIS), with small bowel inflammation at MRI assessed by a semi-quantitative scale, and with response to therapy. 4, 5 Fecal calprotectin can also predict clinical relapse of CD with a sensitivity and specificity ranging between 60 and 100%. 5, 6 Nevertheless, collecting stools is a hurdle for the patient and a blood marker may be more convenient for routine practice. In rheumatoid arthritis, serum calprotectin is well correlated to disease activity, 6, 7 but very few data are available in IBD. 8, 9 The STORI trial prospectively assessed the time to relapse and the predictive factors of relapse after infliximab withdrawal, in a cohort of patients treated for more than one year by combined therapy with an anti-metabolite and in stable remission without steroids for more than six months. 7 In univariate analysis, fecal calprotectin was the strongest predictor of the time-to-relapse.
The aim of our work was to assess the performances of serum calprotectin in the STORI cohort. In particular we looked at its correlation with clinical disease activity (Crohn's disease activity index (CDAI)), biologic activity (C-reactive protein (CRP) and fecal calprotectin), endoscopic activity (CDEIS) as well as at its ability to predict CD relapse and response to treatment.
Material and methods

Study design and patients clinical information
The design of the STORI study has been described in details elsewhere. 7 Briefly, the patients were prospectively recruited in several hospitals in France and Belgium, between 2006 and 2009. The study protocol was accepted by the ethics committee of the St Louis Hospital, Paris and all other participating centers in 2005. All the patients provided their informed consent before screening both for the core study and ancillary studies. Patients who were included in the study were in clinical remission with a CDAI b 150 under a combined treatment with infliximab (IFX) and anti-metabolites (azathioprine (N 2 mg/kg), 6-mercaptopurine (N 1.5 mg/kg) or methotrexate (N 15 mg weekly)) for at least one year and had been corticosteroid-free over the last 6 months. At baseline, CDEIS was evaluated by ileocolonoscopy and serum and stool samples were collected on the same day (the stool sample was collected the day of blood sampling but was not necessarily the first stool of the day). Patients were followed up with a CDAI calculation on a two monthly basis. Relapsing patients presented a CDAI above 250 points or between 150 and 250 points with a 70 points increase from baseline over two consecutive weeks. In case of relapse, the patients were retreated with IFX, resuming scheduled maintenance infusions. Stool and blood samples were collected at the time of relapse and one month after first IFX retreatment, on the same day. Median follow-up time ± SE was 28 ± 2 months. Out of the 115 patients studied, 52 were relapsers. Table 1 summarizes clinical data of the included patients. Moreover, some healthy controls (n = 40) were also tested for serum calprotectin to determine value in a normal population (see Table 1 ). These healthy subjects were prospectively recruited, after giving their informed consent, in the setting of a broader study approved by the ethics committee at Liège University Hospital in 2005. Those were patients undergoing colonoscopy for colorectal cancer screening and confirmed as healthy by specialized gastroenterologists.
Sample parameters measurements
Sera were stored at − 80°C and analyzed using the turbidimetric technique for high sensitivity CRP (hsCRP) quantitation, ranging from 0.06 to 160 mg/L and serum calprotectin quantitation using the CALPROLAB™ ELISA ALP (Lysaker, Norway) according to manufacturer's recommendations. Limit of quantification (LOQ) for this kit is 5 ng/mL and max coefficient of variation (CV) for inter-assay is 10% for EDTA plasma samples. The same kit lot number was used for all the samples tested. Overall 103 serum samples were available for these analyses at baseline, 31 at relapse, and 24 after infliximab retreatment.
Stools samples were stored at −80°C and fecal calprotectin was measured using PhiCal® ELISA (Lysaker, Norway) test after feces extraction of 0.1 g, using 20 μL of supernatant, according to manufacturer instructions and as detailed previously. 7 Overall 88 stool samples were available for these analyses at baseline, 22 at relapse and 15 after infliximab retreatment.
Study methodology and statistics
Correlation between serum calprotectin, hsCRP, fecal calprotectin, and CDAI: to be able to assess serum calprotectin in a wide range of disease activity situations, for the correlations between serum calprotectin and CDAI as well as fecal calprotectin, hsCRP and other blood parameters, we used a mix of samples from the STORI cohort. We included a subset of patients at baseline, all in clinical remission defined by CDAI b 150 (n = 73), and a subset of patients at relapse, all with active disease defined by a CDAI N 150 (n = 30).
Correlation between serum calprotectin and CDEIS: for the correlation between serum calprotectin and endoscopic activity of the disease, we used only patients at baseline (n = 103) as endoscopic assessment was only performed at this time point. The values of the studied parameters were also compared between groups according to CDEIS thresholds as previously proposed by the GETAID. 7 The CDEIS cut-off values and numbers of patients in each group were as follows: CDEIS = 0 (n = 38); CDEIS[0-3] (n = 45); CDEIS N 3 (n = 20).
Sensitivity to change after treatment: for the assessment of response to treatment, we used all the relapsers who were retreated and assessed 1 month after retreatment and for whom we had serum sample at baseline, at retreatment and at one month assessment after retreatment (n = 13 for hsCRP, n = 10 for fecal calprotectin and n = 20 for serum calprotectin).
Relapse prediction: for the assessment of the ability to predict relapse, we used all patients' samples available at baseline (n = 103) and first studied the ability of serum calprotectin to predict time-to-relapse and then assessed its added value over hsCRP and fecal calprotectin, previously assessed in the main study of the STORI trial. 10 
Statistics
Comparison of a continuous variable between two groups was done with a Mann-Whitney test or the unpaired t test with Welch's correction. Correlation of two continuous variables was assessed by a Pearson or a Spearman correlation coefficient. The evolution of biomarkers between baselines, relapse and after retreatment was evaluated by the Wilcoxon matched paired sign-rank test. The Cox regression model was used to evaluate time to relapse (expressed in days) with respect to baseline serum calprotectin, first considered as a continuous variable (with logarithm transformation) and second as a discrete variable according to median or percentile 25 (P25). The time-to-relapse for patients was illustrated by the KaplanMeier curve (data not shown) and the comparison between the two groups was done using a log rank test. We also evaluated the added value of baseline serum calprotectin to hsCRP and fecal calprotectin for predicting relapse, using a Cox model with all parameters taken together or stepwise and considered as continuous variables (with logarithm transformation) or as discrete ones, splitting data using the following thresholds: 5 mg/L for hsCRP, the P25 for serum calprotectin and 250 μg/g for fecal calprotectin. Similarly, we applied a logistic regression model with respect to covariates to predict mucosal healing (CDEIS ≤ 3). For these multivariate analyses, only 79 patients were utilized as showing available data for all 3 parameters. Results were considered to be significant at the 5% level (P b 0.05). Statistical analyses were performed using Prism™ vs5.01 (La Jolla, USA) and SAS version 9.2 (SAS institute, Cary, NC, USA).
Results
Serum calprotectin
The median serum calprotectin was 8892 ng/mL (P25 = 5675 ng/mL, range: 410-125,000 ng/mL) in the CD patients as compared with 1318 ng/mL (range: 215.8-3770 ng/mL) in controls (P b 0.0001). Serum calprotectin was significantly higher in patients with active disease (median = 19,584 ng/mL) than in patients with inactive disease (median = 8353 ng/mL) (P b 0.0001). 
Analyses of correlations
Correlations between serum calprotectin and CDAI, serum hsCRP, fecal calprotectin and CDEIS are shown in Table 2 . Serum calprotectin correlated positively with hsCRP and CDAI. The correlation with fecal calprotectin was weaker and there was no significant correlation with CDEIS. Fecal calprotectin significantly correlated with CDEIS. Fig. 1 shows the distribution of the clinical and biological parameters according to CDEIS level. Only fecal calprotectin showed a significantly different distribution between the CDEIS = 0, CDEIS[0-3] and CDEIS N 3 groups.
Logistic regression model (n = 79) showed a significant association between mucosal healing (CDEIS b 3) and logarithm transformed fecal calprotectin (P = 0.024, HR: 1.6). None of the logistic regression models tested using the serum calprotectin or CRP taken as continuous or discrete variables and considered alone or combined provided significant result. The model using the 3 parameters together (n = 79) did not surpass fecal calprotectin alone. The stepwise logistic regression model (n = 79) only selected logarithm transformed fecal calprotectin and provided similar results (P = 0.025, HR: 1.6). Fig. 2 shows the evolution of hsCRP, fecal and serum calprotectin at baseline, relapse (first retreatment infusion) and 1 month after retreatment in relapsing patients. Serum calprotectin and hsCRP distributions were significantly different between the baseline and relapse. The 3 parameters distributions were also significantly different between relapse and one month after retreatment. None of these parameters showed a significant difference in distribution between baseline Table 2 Correlation coefficient (r, spearman and associated P value) between hsCRP, fecal and serum calprotectin, CDAI and CDEIS. Figure 1 Serum, fecal calprotectin, hsCRP and CDAI distributions for patients grouped according to CDEIS thresholds. All patients were assessed at baseline of the STORI trial. Significant differences between any of the groups (Mann-Whitney test or Unpaired t test with Welch's correction when applicable) are provided. Dots represent the specific parameters value for each patient and the horizontal line is the median of the population.
Evolution of biological parameters during follow-up of retreated relapsing patients
and one month after re-treatment. None of the patients showed an increase in hsCRP after retreatment. A few patients showed an increase in serum (n = 2) or in fecal calprotectin (n = 1) after retreatment, however this did not correlated to absence of clinical response (assessed by CDAI).
Serum calprotectin as a predictor of relapse after IFX withdrawal
Serum calprotectin distribution at baseline was not significantly different between relapsers and non-relapsers (Fig. 3) . Using the time-dependent Cox model, serum calprotectin was not associated with the time-to-relapse, neither as a continuous (P = 0.39) nor as a discrete variable split into two categories according to the median (P = 0.16) or the percentile 25 (P = 0.12). Multivariate analysis (n = 79) including serum calprotectin, hsCRP and fecal calprotectin as continuous variables, for time-to-relapse prediction, indicated that both fecal calprotectin and serum calprotectin were predictors of time-to-relapse (P b 0.0001 and P = 0.0468; HR: 1.851 and 1.725 respectively for fecal and serum calprotectins). The multivariate model (n = 79) using the variables according to the specific cut-off levels tested (P25 for serum calprotectin, 5 mg/L for hsCRP and 250 ng/g for fecal calprotectin), provided significant results with P = 0.0173, 0.0024 and 0.0002; HR: 3.191, 3.561 and 4.120, for serum calprotectin, hsCRP and fecal calprotectin respectively.
Discussion
In the present work, serum calprotectin was significantly correlated to serum hsCRP. Both correlated similarly to CDAI and significantly decreased after IFX treatment in patients with active disease. The correlation between serum and fecal calprotectin was weak but significant. Serum calprotectin did not correlate with endoscopic activity measured by CDEIS while fecal calprotectin did. When combined with fecal calprotectin and hsCRP in a multivariate model, it improved the prediction of clinical relapse after IFX withdrawal but not the prediction of mucosal healing. Only few data were available so far regarding serum calprotectin in CD. 8, 9 In a study by Leach et al., pediatric IBD patients were compared to normal subjects and to children with celiac disease. Calprotectin was significantly raised in the serum of CD and ulcerative colitis patients compared to controls, celiac disease and to unclassified IBD cases. Serum calprotectin was correlated with CRP and the pediatric Crohn's disease activity index (PCDAI). In a study by Malickova et al., changes in serum calprotectin levels were evaluated in 29 anti-TNF naïve IBD patients after their first IFX infusion. Serum calprotectin, as well as CRP and IL-6 decreased in responding patients and the strongest decrease was seen 10 weeks after IFX.
In the present work, although the performances of serum calprotectin and CRP as a biomarker of CD were relatively similar, the correlation between them was only partial which may reflect their different origin. CRP is a serum acute phase reactant protein which synthesis by hepatocytes reflects short term inflammation, with a peak at 48 h after stimulation. IL6 and IL-1β synergize in the activation of its synthesis. Its half-life in plasma is 19 h and circulating CRP mainly depends on the intensity of the pathological process stimulating its production. CRP is also produced in other cell types as monocytes, lymphocytes and mesenteric fat in CD. 2, 8, 9 Calprotectin synthesis occurs in activated neutrophils, macrophages, epithelial cells and monocytes. Its localization is mainly cytosolic (up to 60% is soluble) but it can also be located into the monocytes membranes. In the context of inflammatory bowel disease, calprotectin produced by mucosal neutrophils and intestinal epithelial cells will mainly be released in the mucosa and the intestinal lumen, giving rise to an elevation of fecal calprotectin. [10] [11] [12] This has been recognized as a powerful marker of inflammation along the gastro-intestinal tract, without being specific for any type of inflammatory disorder. Its main asset is to differentiate between irritable bowel syndrome and inflammatory bowel disease, where it may approach a sensitivity and specificity close to 90%. The half-life of calprotectin in plasma is around 5 h. 7 Serum CRP and serum calprotectin can thus be both considered as acute phase reactants, but their synthesis rate, half-life or clearance in serum, are different. These differences may explain why serum calprotectin and hsCRP appear complementary and not fully redundant in the prediction of relapse in CD. These two markers, together with fecal calprotectin, may thus optimize the ability to predict relapse, particularly in the setting of infliximab discontinuation.
Although not assessed on strictly similar samples due to some missing values for fecal calprotectin, our results indicate that contrarily to fecal calprotectin, neither serum calprotectin nor hsCRP were associated with mucosal healing. Furthermore they showed no added value to this fecal marker in the multivariate analysis. Until now, only fecal markers, including lactoferrin and calprotectin have shown a clinically relevant correlation with mucosal healing, while blood markers seem to correlate better with clinical activity of the disease.
Our study presents some limitations. First, the correlation between serum calprotectin and the endoscopic lesions assessed by the CDEIS could only be studied at the baseline of the STORI trial. Only a few patients had significant endoscopic disease. Thus, the absence of correlation between serum calprotectin and endoscopic activity measured by CDEIS must be taken with caution, as it remains possible that more severe endoscopic activity of the disease would be associated with a higher serum calprotectin level. Second, the relapse predictive value of serum calprotectin in a multivariate model was only demonstrated for patients being withdrawn from IFX. Whether it can be extrapolated to other clinical situations remains to be demonstrated.
In conclusion, as a biomarker for CD, serum calprotectin appears to have a profile very similar to hsCRP, with a significant increase in active disease and a good responsiveness to medical therapy. Furthermore it appears complementary to hsCRP and fecal calprotectin for relapse prediction after IFX withdrawal. Further investigations are required to better determine its specific use in the monitoring of CD patients in routine practice.
